Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Protenova Co. Ltd. focuses its patent efforts in the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 1 pending office action. This matter is being handled by 1 distinct examiner within 1 distinct art unit, showing a singular point of contact for the company's current patent office interactions. This level of concentration is typical for companies focusing on a specific biological sequence or pharmaceutical formulation that requires specialized expertise.
ROBINSON, HOPE A is the busiest examiner assigned to the portfolio, managing 1 busiest_examiner_pending action. The prosecution strategy is currently limited to this single active case, meaning the company's immediate success in this technology area is tied to the findings of this specific examiner. Practitioners must focus their efforts on the specific requirements of this examiner, as there are no other pending actions to provide a broader view of how the patent office might treat the company's technology. The use of 1 distinct art unit confirms that the examination is being conducted within a single specialized group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268941 | IMMUNOGLOBULIN-BINDING POLYPEPTIDE | ROBINSON, HOPE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268941 | IMMUNOGLOBULIN-BINDING POLYPEPTIDE | ROBINSON, HOPE A | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18268941 | IMMUNOGLOBULIN-BINDING POLYPEPTIDE | ROBINSON, HOPE A | 1652 | §103§112 | Final Rejection | — | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProtenova Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hope A Robinson has the most, with 1 of Protenova Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
